NCT02139696

Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation

Does Targeting of Sphingosine-1 Phosphate Receptors Reduce Microglial Activation in Multiple Sclerosis? A [11C]PK11195 Brain PET Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10 (actual)
• Sponsor: Turku University Hospital · Other Government
• Sex: All
• Age: 18 Years – 58 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the usability of positron emission tomography imaging as a novel outcome measure in multiple sclerosis studies

Detailed description

Background and Rationale In multiple sclerosis (MS), significant pathology correlating to disease progression, to expanded disability status scale (EDSS) and to cognitive decline, takes place outside the plaque areas, i.e. in areas of normal appearing white matter and gray matter. Neuropathological studies suggest that mechanisms involved in this widespread pathology include activation of microglial cells, oxidative stress and deficiency in mitochondrial functions. Activated microglia can be detected in vivo with a translocator protein (TSPO), expressed in activated, but not resting microglia) binding radioligands and positron emission tomography (PET). 11Carbon-PK11195 radioligand is one such radioligand. Importantly, the possible effect of MS therapies on microglial activity can be evaluated in patients in vivo with PET-imaging performed before and after the treatment.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
RADIATION	PET and MRI	Patients will be imaged using PET and MRI at baseline, and twice during treatment

Timeline

• Start date: 2013-09-01
• Primary completion: 2015-01-01
• Completion: 2016-10-01
• First posted: 2014-05-15
• Last updated: 2018-05-11

Locations

1 site across 1 country: Finland